Swiss biopharma ADC Therapeutics announced the closure of its UK R&D site and layoffs trimming its workforce by 30%, following the discontinuation of its only clinical-stage candidate for B-cell acute lymphoblastic leukemia. Early development for certain solid tumor antibody-drug conjugates was halted to reallocate resources towards the marketed monoclonal antibody Zynlonta and a prostate-specific membrane antigen-targeted candidate. The restructuring aims to focus capital on prioritized assets amid clinical setbacks and trial terminations for multiple pipeline drug programs over recent quarters.